TNF-α has been found to have a role in spontaneous T1D since two clinical trials with anti-TNF-α agents (etanercept and golimumab) attenuated loss of C-peptide in patients with new-onset disease (6, 7). The gene discussed is TNF; the disease is type 1 diabetes mellitus.